Researchers discovered three powerful peptides in silkworm pupae that block the enzyme responsible for raising blood pressure, with one peptide (MQGFIPE) showing particularly strong effects in laboratory tests. According to Gram Research analysis, this 2026 study identified these compounds through computer screening and confirmed their activity in test tubes, suggesting silkworm pupae could become a natural source for blood pressure-lowering supplements, though human studies are still needed.
Researchers discovered that silkworm pupae contain special proteins called peptides that could help control high blood pressure. According to Gram Research analysis, scientists identified three powerful peptides from silkworm pupae that block an enzyme in your body responsible for raising blood pressure. Using computer modeling and lab tests, they found that one peptide called MQGFIPE worked especially well at stopping this enzyme. While this is early-stage research conducted in laboratory settings, it suggests silkworm pupae could become a natural ingredient in blood pressure supplements in the future.
Key Statistics
A 2026 laboratory study published in Biochimie identified three ACE-inhibitory peptides from silkworm pupae, with MQGFIPE demonstrating the strongest inhibitory activity at an IC50 of 0.21 ± 0.036 mg/mL.
Molecular docking simulations in the silkworm pupa peptide study revealed that MQGFIPE and PNDIL functioned as mixed-type inhibitors while ADNIPIK acted as a non-competitive inhibitor, indicating multiple mechanisms of blood pressure enzyme blockade.
Spectral analysis of the three silkworm-derived peptides showed they effectively altered the ACE enzyme’s conformation and quenched its intrinsic fluorescence, with molecular dynamics simulations confirming stable binding to the enzyme complex.
The Quick Take
- What they studied: Whether proteins found in silkworm pupae could block an enzyme that raises blood pressure, and how they work at the molecular level
- Who participated: This was laboratory research using silkworm pupa samples and computer simulations—no human participants were involved in this study
- Key finding: Three peptides from silkworm pupae effectively blocked the blood pressure-raising enzyme, with MQGFIPE showing the strongest effect (IC50 = 0.21 mg/mL)
- What it means for you: Silkworm pupae could potentially become a natural supplement ingredient for blood pressure management, though much more research including human trials is needed before any health claims can be made
The Research Details
Researchers started by analyzing the genetic sequences of proteins in silkworm pupae using computers to predict which ones might block blood pressure-raising enzymes. They then purified these proteins from actual silkworm pupae using special laboratory techniques. Next, they tested these proteins in test tubes to see if they actually worked. To understand how they worked, scientists used advanced computer simulations to watch how the proteins attached to the enzyme at the molecular level, like watching puzzle pieces fit together. They also used special light-based techniques to observe changes in the enzyme’s structure when the proteins attached to it.
This multi-step approach combining computer prediction, lab testing, and molecular visualization is important because it helps researchers understand not just whether something works, but exactly how it works. This detailed understanding is necessary before moving to human testing and potential medical applications.
This is laboratory research published in a peer-reviewed scientific journal, which means other experts reviewed it before publication. However, because it was conducted entirely in test tubes and computer simulations without human participants, the results cannot yet be applied to real people. The study is a solid foundation for future research but represents an early stage of scientific investigation.
What the Results Show
Scientists identified three peptides (MQGFIPE, PNDIL, and ADNIPIK) that effectively blocked the ACE enzyme responsible for raising blood pressure. MQGFIPE was the most powerful, requiring only 0.21 mg/mL to achieve 50% inhibition. PNDIL came in second at 0.569 mg/mL, and ADNIPIK third at 0.849 mg/mL. These results suggest silkworm pupae contain naturally occurring compounds that could mimic the effects of blood pressure medications. The peptides worked through different mechanisms—two functioned as mixed-type inhibitors (blocking the enzyme in multiple ways), while one worked as a non-competitive inhibitor (blocking the enzyme through a different pathway).
Molecular docking studies revealed that the peptides attached to the enzyme through hydrogen bonds and hydrophobic interactions, similar to how magnets stick to metal. Spectral analysis showed the peptides changed the enzyme’s shape and altered the environment around its amino acids, essentially disabling it. Molecular dynamics simulations confirmed these peptides stayed stably attached to the enzyme over time, suggesting they would maintain their effect.
This research builds on decades of studies showing that natural peptides from food sources can lower blood pressure. Previous research identified ACE inhibitors in sources like milk, fish, and plants. This study adds silkworm pupae to the list of natural sources and provides detailed molecular explanations for how these specific peptides work, advancing our understanding of natural blood pressure management.
This study was conducted entirely in laboratory settings using test tubes and computer models—no human participants were involved. The results cannot be directly applied to people yet. The study did not test whether these peptides survive digestion or are absorbed into the bloodstream when eaten. Long-term safety and effectiveness in humans remain unknown. The sample size and specific experimental conditions were not fully detailed in the abstract.
The Bottom Line
This research suggests silkworm pupae could be a promising natural source for blood pressure-lowering compounds. However, confidence in practical recommendations is currently low because human studies have not been conducted. Anyone with high blood pressure should continue following their doctor’s treatment plan rather than relying on silkworm pupa supplements, which are not yet proven safe or effective in people.
This research is most relevant to supplement manufacturers, food scientists, and pharmaceutical researchers exploring natural alternatives to blood pressure medications. People with high blood pressure should be aware of this emerging research but should not change their treatment without consulting their doctor. This is not yet ready for consumer use.
This is early-stage research. If development continues, it could take 5-10 years or more before silkworm pupa peptides could be tested in humans, and several more years before any products might reach the market. Realistic expectations should account for this lengthy development timeline.
Frequently Asked Questions
Can silkworm pupae help lower blood pressure?
Laboratory research shows silkworm pupae contain peptides that block blood pressure-raising enzymes in test tubes. However, human studies haven’t been conducted yet, so it’s unknown whether these compounds work in people or survive digestion.
What is MQGFIPE and why is it important?
MQGFIPE is a peptide (protein fragment) found in silkworm pupae that showed the strongest ability to block ACE, the enzyme responsible for raising blood pressure. It required only 0.21 mg/mL to achieve 50% inhibition in laboratory tests.
Are silkworm pupa supplements available to buy now?
No. This research is in early laboratory stages. Products would require human safety and effectiveness testing before becoming available to consumers, a process that typically takes many years.
How do these silkworm peptides lower blood pressure?
The peptides attach to the ACE enzyme through chemical bonds and hydrophobic interactions, changing its shape and disabling its ability to raise blood pressure. Different peptides use slightly different blocking mechanisms.
Should I stop taking my blood pressure medication for silkworm pupae?
No. Continue taking prescribed blood pressure medications as directed by your doctor. Silkworm pupa research is preliminary and not yet proven safe or effective in humans. Never change medications without medical guidance.
Want to Apply This Research?
- Users interested in natural blood pressure management could track their blood pressure readings weekly using the app’s health metrics feature, noting any dietary changes or supplements they try, to establish a personal baseline for future comparison if silkworm pupa products become available
- While silkworm pupa supplements are not yet available, users can use the app to track proven blood pressure-lowering behaviors like daily exercise, sodium reduction, and stress management, preparing for potential future integration of emerging natural supplement options
- Set up monthly blood pressure tracking in the app with reminders, and create a research interest tag for ’emerging natural supplements’ to monitor when silkworm pupa products become available for consumer use, allowing users to make informed decisions when evidence-based products launch
This article discusses early-stage laboratory research on silkworm pupa peptides and blood pressure. These findings have not been tested in humans and should not be used as medical advice. Silkworm pupa supplements are not currently approved by regulatory agencies for treating high blood pressure. Anyone with high blood pressure should continue following their doctor’s treatment recommendations and should not replace prescribed medications with unproven supplements. Consult your healthcare provider before making any changes to your blood pressure management plan or before using any new supplements.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.